secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001558370-24-002313
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala Bio targeting CHASE Phase 2b data for KPI-012 (PCED) by end of 2024
------------------------------------------------------------------------

- Topline safety and efficacy data from CHASE Phase 2b trial expected by year-end 2024.
- KPI-012 is a human mesenchymal stem cell secretome for persistent corneal epithelial defect.
- Corporate presentation posted on investors section of company website; no other material updates.
- No financial guidance or operational changes disclosed in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837024002313/0001558370-24-002313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837024002313/kala-20240304x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-002313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer